Literature DB >> 15831957

Generation of recombinant influenza A virus without M2 ion-channel protein by introduction of a point mutation at the 5' end of the viral intron.

T K W Cheung1, Y Guan1, S S F Ng1, H Chen1, C H K Wong1, J S M Peiris1, L L M Poon1.   

Abstract

The aim of this study was to inhibit influenza virus M2 protein expression by mutating the splicing signal of the M gene. Mutations were introduced into the GU dinucleotide sequence at the 5'-proximal splicing site of the M gene (corresponding to nt 52-53 of M cRNA). Transfected cells expressing mutated M viral ribonucleoproteins failed to generate M2 mRNA. Interestingly, recombinant viruses with mutations at the dinucleotide sequence were viable, albeit attenuated, in cell culture. These recombinants failed to express M2 mRNA and M2 protein. These observations demonstrated that the GU invariant dinucleotide sequence at the 5'-proximal splicing site of M gene is essential for M2 mRNA synthesis. These results also indicated that the M2 ion-channel protein is critical, but not essential, for virus replication in cell culture. This approach may provide a new way of producing attenuated influenza A virus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15831957     DOI: 10.1099/vir.0.80727-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  16 in total

1.  Mutations at alternative 5' splice sites of M1 mRNA negatively affect influenza A virus viability and growth rate.

Authors:  Chiayn Chiang; Guang-Wu Chen; Shin-Ru Shih
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

2.  Mutational analysis of cis-acting RNA signals in segment 7 of influenza A virus.

Authors:  Edward C Hutchinson; Martin D Curran; Eliot K Read; Julia R Gog; Paul Digard
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

Review 3.  Influenza virus assembly and budding.

Authors:  Jeremy S Rossman; Robert A Lamb
Journal:  Virology       Date:  2011-01-14       Impact factor: 3.616

4.  Human annexin A6 interacts with influenza a virus protein M2 and negatively modulates infection.

Authors:  Huailiang Ma; François Kien; Maxime Manière; Yang Zhang; Nadège Lagarde; Kong San Tse; Leo Lit Man Poon; Béatrice Nal
Journal:  J Virol       Date:  2011-11-23       Impact factor: 5.103

5.  Mutations in the membrane-proximal region of the influenza A virus M2 protein cytoplasmic tail have modest effects on virus replication.

Authors:  Shaun M Stewart; Andrew Pekosz
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

6.  Influenza virus M2 protein mediates ESCRT-independent membrane scission.

Authors:  Jeremy S Rossman; Xianghong Jing; George P Leser; Robert A Lamb
Journal:  Cell       Date:  2010-09-17       Impact factor: 41.582

7.  Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication.

Authors:  Alexander Karlas; Nikolaus Machuy; Yujin Shin; Klaus-Peter Pleissner; Anita Artarini; Dagmar Heuer; Daniel Becker; Hany Khalil; Lesley A Ogilvie; Simone Hess; André P Mäurer; Elke Müller; Thorsten Wolff; Thomas Rudel; Thomas F Meyer
Journal:  Nature       Date:  2010-01-17       Impact factor: 49.962

8.  Stepwise priming by acidic pH and a high K+ concentration is required for efficient uncoating of influenza A virus cores after penetration.

Authors:  Sarah Stauffer; Yuehan Feng; Firat Nebioglu; Rosalie Heilig; Paola Picotti; Ari Helenius
Journal:  J Virol       Date:  2014-08-27       Impact factor: 5.103

9.  The influenza A virus spliced messenger RNA M mRNA3 is not required for viral replication in tissue culture.

Authors:  David Jackson; Robert A Lamb
Journal:  J Gen Virol       Date:  2008-12       Impact factor: 3.891

10.  Identification of a novel splice variant form of the influenza A virus M2 ion channel with an antigenically distinct ectodomain.

Authors:  Helen M Wise; Edward C Hutchinson; Brett W Jagger; Amanda D Stuart; Zi H Kang; Nicole Robb; Louis M Schwartzman; John C Kash; Ervin Fodor; Andrew E Firth; Julia R Gog; Jeffery K Taubenberger; Paul Digard
Journal:  PLoS Pathog       Date:  2012-11-01       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.